Advanced Cardiovascular Risk Panel

Knowing your Lp(a) level changes clinical management even though Lp(a) itself is not readily modifiable. If your Lp(a) is elevated, it means your cardiovascular risk is significantly higher than your standard lipid panel suggests — and therefore the thresholds for starting statin therapy, achieving a lower LDL target, and managing other risk factors more aggressively are all shifted. Cardiologists in the UK and internationally increasingly recommend treating Lp(a) as a ‘multiplier’ of standard risk: it tells you to treat your other risk factors harder. Emerging RNA therapies specifically targeting Lp(a) are in late clinical trials and may become available within the next few years.

The European Atherosclerosis Society recommends considering Lp(a) above 50 mg/dL (approximately 107 nmol/L) as elevated and a significant cardiovascular risk factor. Very high levels (above 180 mg/dL) carry a risk equivalent to heterozygous familial hypercholesterolaemia. Because Lp(a) is genetically determined, it only needs to be measured once in most individuals unless clinical context changes. Interestingly, South Asian, African, and African-Caribbean individuals tend to have higher Lp(a) levels on average than European individuals — population-specific context matters.

Elevated homocysteine is thought to damage the endothelium (the inner lining of blood vessels) through oxidative stress and direct cytotoxic effects, promoting inflammation, platelet aggregation, and arterial stiffness. It is also associated with increased thrombotic risk (blood clot formation). The accumulation of homocysteine in the blood occurs when the B-vitamin-dependent pathway that converts it to methionine or cysteine is impaired — either due to B12, folate, or B6 deficiency, or genetic variants in the MTHFR enzyme. Correcting deficiency through B-vitamin supplementation reliably lowers homocysteine levels.

Yes. Pre-diabetes (HbA1c 42 to 47 mmol/mol) is associated with significantly elevated cardiovascular risk — independent of standard lipid levels, blood pressure, and obesity. This is because elevated blood glucose promotes endothelial dysfunction, oxidative stress, inflammation, and accelerated atherosclerosis, even at pre-diabetic levels. Including HbA1c in a cardiovascular risk assessment identifies people who are ‘normal’ by cholesterol alone but who are accruing cardiovascular risk through the metabolic channel. It also flags those who should receive early lifestyle or pharmacological intervention to prevent progression to type 2 diabetes.

The most effective way to reduce ApoB is to reduce LDL cholesterol, since each LDL particle carries one ApoB molecule. However, the same LDL reduction produces a greater relative reduction in ApoB in people with smaller, denser LDL particles (who have more particles per unit of LDL cholesterol). This means that in people with metabolic syndrome, weight loss and dietary changes that specifically reduce small dense LDL produce disproportionate improvements in ApoB relative to measured LDL cholesterol. PCSK9 inhibitors, which lower LDL by 50 to 60%, produce equivalent reductions in ApoB and are the most powerful tools currently available for ApoB reduction alongside statins.

Ideally at 35 for most adults, or earlier for those with a strong family history of premature cardiovascular disease (heart attack before 60 in a first-degree relative) or familial hypercholesterolaemia. Lp(a) testing once establishes your baseline genetic risk level. ApoB should be measured alongside LDL as part of comprehensive cardiovascular risk assessment, particularly if you have metabolic syndrome, diabetes, or other risk factors. Younger adults with concerning family histories may benefit from testing even earlier — knowing your cardiovascular risk profile at 30 gives you decades of opportunity to modify other risk factors.